Pfizer's blockbuster blood thinner sales boost third-quarter results

Statements (3)

1. ▲ Bullish

   Pfizer's third-quarter results exceeded expectations due to demand for Padcev and Eliquis.

   rte.ieNov 3, 2026 14:40 UTCHigh importance
2. ● Neutral

   Pfizer's Eliquis sales grew while COVID and Prevnar sales fell

   nasdaq.comNov 3, 2026 14:33 UTCHigh importance
3. ▲ Bullish

   Eliquis, a blockbuster blood thinner, helped Pfizer post better-than-expected third-quarter results.

   bnnbloomberg.caNov 3, 2026 14:04 UTCHigh importance